Recent multicenter studies have demonstrated that the densities of CD3+ and CD8+ T cells are the most important markers for predicting the prognosis of CRC.[14, 15] Therefore enhancing endogenous antitumor T cell responses in CRC by ICI therapy could be an important clinical issue. This evidence concerns the gene CD8A and colorectal carcinoma.